The current standards of care involve using anti-VEGF agents, which selectively target extracellular VEGF. We've been doing this for years and those drugs do a good job, but there are limitations ...
A low risk of adverse safety outcomes was observed in anti–vascular endothelial growth factor (VEGF) intravitreal injections performed in office-based and operating room settings, with a higher rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback